首页> 外文期刊>EJNMMI Research >Pharmacokinetic modeling of P-glycoprotein function at the rat and human blood–brain barriers studied with (R)-[11C]verapamil positron emission tomography
【24h】

Pharmacokinetic modeling of P-glycoprotein function at the rat and human blood–brain barriers studied with (R)-[11C]verapamil positron emission tomography

机译:(R)-[11C]维拉帕米正电子发射断层显像技术研究大鼠和人血脑屏障中P-糖蛋白功能的药代动力学模型

获取原文
       

摘要

Background This study investigated the influence of P-glycoprotein (P-gp) inhibitor tariquidar on the pharmacokinetics of P-gp substrate radiotracer (R)-[11C]verapamil in plasma and brain of rats and humans by means of positron emission tomography (PET). Methods Data obtained from a preclinical and clinical study, in which paired (R)-[11C]verapamil PET scans were performed before, during, and after tariquidar administration, were analyzed using nonlinear mixed effects (NLME) modeling. Administration of tariquidar was included as a covariate on the influx and efflux parameters (Qin and Qout) in order to investigate if tariquidar increased influx or decreased outflux of radiotracer across the blood–brain barrier (BBB). Additionally, the influence of pilocarpine-induced status epilepticus (SE) was tested on all model parameters, and the brain-to-plasma partition coefficient (VT-NLME) was calculated. Results Our model indicated that tariquidar enhances brain uptake of (R)-[11C]verapamil by decreasing Qout. The reduction in Qout in rats during and immediately after tariquidar administration (sevenfold) was more pronounced than in the second PET scan acquired 2 h after tariquidar administration (fivefold). The effect of tariquidar on Qout in humans was apparent during and immediately after tariquidar administration (twofold reduction in Qout) but was negligible in the second PET scan. SE was found to influence the pharmacological volume of distribution of the central brain compartment Vbr1. Tariquidar treatment lead to an increase in VT-NLME, and pilocarpine-induced SE lead to increased (R)-[11C]verapamil distribution to the peripheral brain compartment. Conclusions Using NLME modeling, we were able to provide mechanistic insight into the effects of tariquidar and SE on (R)-[11C]verapamil transport across the BBB in control and 48 h post SE rats as well as in humans.
机译:背景本研究通过正电子发射断层扫描(PET)研究了P-糖蛋白(P-gp)抑制剂tariquidar对P-gp底物示踪剂(R)-[11C]维拉帕米在大鼠和人血浆和脑中的药代动力学的影响。 )。方法从临床前和临床研究中获得的数据进行分析,其中使用非线性混合效应(NLME)模型分析了在使用tariquidar之前,期间和之后进行的配对(R)-[11C]维拉帕米PET扫描。为了研究tariquidar跨血脑屏障(BBB)流入或减少放射性示踪剂的流出量,将tariquidar的使用作为流入和流出参数(Qin和Qout)的协变量。此外,测试了毛果芸香碱引起的癫痫持续状态(SE)对所有模型参数的影响,并计算了脑-血浆分配系数(VT-NLME)。结果我们的模型表明,tariquidar通过降低Qout来增强(R)-[11C]维拉帕米的大脑摄取。在使用tariquidar后2小时(五倍)进行的第二次PET扫描中,大鼠在使用tariquidar期间和给药后立即Qout降低(七倍)。在使用tariquidar期间和给药后立即(在Qout中降低两倍),t利奎达对人的Qout的影响是显而易见的,但在第二次PET扫描中可忽略不计。发现SE影响中枢脑室Vbr1的药理分布量。 Tariquidar治疗导致VT-NLME升高,毛果芸香碱诱导的SE导致(R)-[11C]维拉帕米向周围脑室的分布增加。结论使用NLME建模,我们能够对塔利基达和SE对(R)-[11C]维拉帕米在对照大鼠和SE后48小时以及人类中通过BBB转运的作用提供机械机理的见解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号